The tumor suppressor gene encoding the cyclindependent kinase inhibitor p16 has, remarkably, been found to encode a second protein, p19, with a distinct sequence translated from an alternative reading frame; like p16, p19 can block the cell cycle in G1 phase.
The protein p16 was initially identified as an inhibitor of cyclin-dependent kinase (Cdk) activity -specifically, it was found to bind and inhibit cyclin D-Cdk4 [1] . This inhibition prevents phosphorylation of the retinoblastoma product (Rb) and progression from G1 to S phases of the cell cycle [2, 3] . Previous observations that the Rb gene is frequently inactivated, and the cyclin D gene amplified, in human cancer cells already pointed to an important role for these regulators of the G1/S transition in neoplasia. Like other Cdk inhibitor genes, such as p21, p16 was thus a candidate tumor suppressor gene, potentially inactivated in human cancer progression. Subsequent studies have established that inactivation of p16 plays a major role in human cancer, and it may be the first mammalian example of a gene that codes two distinct proteins using overlapping reading frames.
As p16 was coming to light, frantic efforts were being made by several groups to clone a critical tumor suppressor gene believed to be located on chromosome 9 in a region, 9p21, which is perhaps the most common site of chromosomal deletions in human cancer. Part of the minimal region containing the putative 9p21 tumor suppressor gene was completely sequenced and found to contain the recently cloned p16 gene [4] . Point mutations in p16 were subsequently identified in familial melanoma patients [5] , many types of tumor cell line [4] , and some types of primary cancer [6] . Reintroduction of p16 into tumor cell lines led to a significant suppression of growth in clonogenic assays, and to a marked increase in G1/S cell-cycle arrest [7] . As expected, reintroduction of p16 into Rb -/-cell lines did not suppress growth, as inactivation of cyclin D-Cdk4 complexes and inhibition of the cell cycle is achieved through the downstream effector Rb [8] .
Genetic studies initially raised doubts about the importance of p16 inactivation in primary neoplasia [9, 10] . We [11] and others did eventually find, however, that in most types of tumor both p16 alleles were deleted; unlike many other tumor suppressor genes, few examples were found where p16 was inactivated by point mutations. It was further found that, in significant number of primary tumors and cell lines, the 'CpG island' upstream of p16 was methylated -a modification previously associated with complete transcriptional inactivation of the gene [12] . Surprisingly, however, tumors with this DNA methylation pattern still produced another abundant p16 transcript.
We and others [13, 14] cloned this alternative transcript, and found that it was derived from a second transcriptional initiation site, more than 18 kilobases (kb) upstream of the previously defined p16 exon 1 (now called 1␣), producing a new transcript with a distinct first exon (called 1␤) spliced on to the remaining p16 exons, 2 and 3 ( Fig. 1) . It was already known that cell lines lacking Rb expressed high levels of p16, leading to suggestions that p16 might be part of an inhibitory feedback loop in which Cdk4 inactivation allows accumulation of unphosphorylated Rb, setting the stage for the next cycle (reviewed in [15] ). Recently, the production of both p16 transcripts, ␣ and ␤, has been shown to be significantly increased after inactivation of Rb by simian virus 40 (SV40) T antigen [16] . The cis DNA sequence mediating this effect for p16 ␣ was mapped to a region ~800-900 base pairs upstream of exon 1␣. Interestingly, exon 1␤ is further upstream and Genomic structure of human p16 gene, showing how the ␣ and ␤ transcripts are transcribed from different initiation sites and encode proteins with completely different amino-acid sequences. Although the two transcripts share exon 2 nucleotide sequences, these are translated in different frames, and translation terminates at different points in the two cases. contains a 'GT box' within its own putative promoter region [13] . The presence of such a separate promoter sequence for p16 ␤ suggests that its transcription may be regulated independently of p16 ␣.
Closer examination of the p16 ␤ transcript revealed that the novel first exon contains an open reading frame potentially extending into exon 2 of p16. However, all three possible reading frames were out of frame with the known coding region of exon 1␣ that extended through exons 2 and 3. This left open some intriguing possibilities. First, that the alternative p16 ␤ transcript is completely untranslated. Second, that exons 1␣ and 1␤ are both untranslated, and the third methionine codon in exon 2, which lies within a possible ribosome entry sequence, initiates the same truncated protein from both transcripts. And third, the most interesting possibility, that a novel protein is produced from one of the putative reading frames starting in exon 1␤.
With regard to the first possibility, it is notable that the p16 ␤ transcript is often more abundant than the p16 ␣ transcript in cell lines [13] . This may reflect a regulatory role played by p16 at the RNA level, either on itself or on other, unknown, genes. With regard to the second possibility, in vitro translation of the p16 ␤ transcript did yield low levels of a 9 kDa protein compatible with translation from the third methionine codon in exon 2 [13] . However, immune precipitation with both polyclonal and monoclonal antibodies against the carboxyl terminus of p16 failed to recognize this product in cell lines. This still left open the improbable possibility that p16 is the first mammalian example of a gene that encodes distinct proteins using overlapping reading frames.
Quelle et al. [17] recently cloned the mouse p16 gene and made polyclonal antibodies against peptides potentially encoded by the longest of the ␤ reading frames. These antibodies identified a novel 19 kDa protein in cells, called p19ARF (Fig. 1) , the size of which is compatible with its translation from this reading frame. Reintroduction of p19ARF into p16 -/-mutant NIH3T3 cells produced marked growth inhibition [17] , characterized by G1/S arrest similar to that caused by p16, and also a significant delay in G2/M. Overexpression of cyclin D was found to overcome the p19ARF-induced G1 block. As expected, given that its sequence shows no similarity to that of p16, there were no indications that p19ARF interacts with cyclin-Cdk complexes. This striking observation implies that one cell-cycle inhibitor is derived from an alternative reading frame overlapping that encoding another critical cell-cycle regulator.
An immediate question arises as to the nature of the p16 ␤ product in humans. Although exon 1␣ is conserved across most species, exon 1␤ is poorly conserved [18] . Moreover, the same reading frame of the human gene would produce a significantly shorter protein product, because of a premature termination codon. Although such 'frame-shifting' is well known in viral systems, it has not been previously observed in higher organisms [19] . With the luxury of a far greater genome size, it is difficult to understand why the same sequence would be used to generate distinct proteins. The possibility of a mutation or deletion knocking out both of two critical genes is much higher if their sequences overlap. In human tumors, the entire p16-containing region is often deleted, so could nature's experiment in frugality have generated an Achilles' heel for neoplasia?
Cancer genetics does not lend strong support to this premise. Quelle et al. [17] point out that previously overlooked point mutations in exon 2 of p16, which do not change the sequence of the ␣ product, could lead to significant alterations of the ␤ product. Furthermore, although the entire p16 gene is deleted in many tumors, a single mutation in exon 2 could inactivate both proteins. But sequence analysis of 50 tumors with an intact p16 ␣ coding capacity revealed no alterations of exon 1␤ [13] . Moreover, in tumors showing methylation upstream of p16, only ␣ expression is inactivated -␤ is still an abundant transcript in these tumor cells. These observations strongly argue that p16 ␤ is not a primary tumorigenic target. I know of only two examples where small deletions knock out only exon 1␤ of p16, one a glioma xenograft [20] and the other a melanoma cell line [21] . However, although p16 ␣ is expressed in these two cases, it is unclear if its normal regulation is intact. Moreover, in both cases the p15 gene, which encodes another cell-cycle inhibitor, is also deleted [22] .
What about functional studies? My own group's unpublished observations strongly support a suppressor role for human p16 ␤. We have found that reintroduction of p16 ␤ in cell lines with wild-type or deleted p16 results in marked growth inhibition, associated with a G1/S arrest, and a significant decrease in clonogenic assays. Interestingly, this suppression is even seen when constitutively overexpressed p16 ␤ is introduced into cell lines in which methylation of p16 blocks expression of the ␣, but not the ␤, product. Furthermore, p16 ␤ may suppress growth of cell lines lacking Rb. If confirmed, this would suggest that the p16 ␤ product has a role either downstream of Rb or on a distinct pathway that also converges on the G1/S checkpoint. It may be relevant that Quelle et al. [17] saw increased p19ARF levels in mouse cell lines with p53 inactivation [17] . It will be of great interest to see if the putative human p16 ␤ protein can be identified in vivo using antibodies; at present the possibility remains that negative cell-cycle regulation is mediated by the ␤ transcripts.
Is p16 ␤ running the same race as p16 ␣, but on a different track? Is it an innocent bystander in cancer, ripped out of the genome in neoplastic cells when p16 ␣ is inactivated, or is it also a primary target of tumorigenic mutations? These and other questions will undoubtedly keep us busy for a long time to come.
